Each of the included studies was graded based on the model type used in the study and on the quality of the parameterisation of the model with regards to the data sources used to obtain estimates for the efficacy of interventions. [...] This process examined the type of model used in the study and assessed the quality of the parameterisation of the model with regards to the data sources used to obtain estimates for the efficacy of interventions. [...] 40 11 FIGURE 1 Illustrative example of the ‘relative reduction in incidence/prevalence at the end of the study period between the baseline and comparison scenarios The key explanatory variables in the analysis are measures of the change in coverage of OAT and NSPs and the increase in DAA treatments. [...] Note that there is a strong association with an increase in DAA coverage, as indicated by the colour coding (10) Note that the value of the regression coefficient for DAA treatment should not be compared with the value of the regression coefficient for the reduction in the coverage gap for OAT and NSPs because the treatment measure is not a percentage, unlike the OAT and NSP measures. [...] Data points were considered ineligible for inclusion in the linear regression analysis if the incidence/prevalence reduction over the study period in the baseline scenario exceeded 99 %, the incidence was less than 0.1 per 100 person-years at the end of the study period or the prevalence was less than 0.1 % at the end of the study period.
Authors
Related Organizations
- Pages
- 54
- Published in
- Portugal
Table of Contents
- Public Health Guidance on prevention and control of infectious diseases among people who inject drugs 1
- 2023 update 1
- Contents 3
- Abbreviations 4
- Executive summary 5
- Methods 5
- Findings 5
- Conclusions 6
- Background 7
- Methods 8
- Research question 8
- PICO and inclusion/exclusion criteria 8
- Data sources and search methods 10
- Study selection 10
- Critical appraisal 10
- Methods for data synthesis 11
- Description of the linear regression analysis 11
- Background 11
- Explanatory and response variables 11
- Results 14
- Opioid agonist treatment 16
- Opioid agonist treatment in prison 16
- Needle and syringe programmes 17
- Combination OAT+NSPs 19
- Combination OAT+NSPs+DAAs 21
- Discussion 22
- Summary of evidence 22
- Strengths and limitations 24
- Conclusions 24
- References 25
- Appendix 1. Tables summarising the evidence from each study 27
- Appendix 2. Linear regression models 43
- Appendix 3. Key statistics for data used in linear regression analysis 50